Chosa Oncology AB (FRA:W5L)
0.0392
+0.0062 (18.79%)
At close: Nov 18, 2026
Chosa Oncology AB Earnings Call Transcripts
Fiscal Year 2026
-
New data show Platin-DRP can predict which advanced lung cancer patients benefit from platinum chemotherapy, with high DRP scores linked to significantly longer survival. Commercialization will focus on licensing to diagnostic and pharma partners, with global market ambitions and strong patent protection.
Fiscal Year 2025
-
A proprietary platform significantly boosts the efficacy of platinum-based chemotherapy in combination with immune therapies, targeting a $150 billion market. Ongoing clinical validation, a royalty-based commercialization model, and a SEK 20 million capital raise support upcoming inflection points, including key study readouts and potential pharma partnerships.